These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

167 related articles for article (PubMed ID: 21884580)

  • 1. Inhibitory effects of the JAK inhibitor CP690,550 on human CD4(+) T lymphocyte cytokine production.
    Migita K; Miyashita T; Izumi Y; Koga T; Komori A; Maeda Y; Jiuchi Y; Aiba Y; Yamasaki S; Kawakami A; Nakamura M; Ishibashi H
    BMC Immunol; 2011 Aug; 12():51. PubMed ID: 21884580
    [TBL] [Abstract][Full Text] [Related]  

  • 2. CP690,550 inhibits oncostatin M-induced JAK/STAT signaling pathway in rheumatoid synoviocytes.
    Migita K; Komori A; Torigoshi T; Maeda Y; Izumi Y; Jiuchi Y; Miyashita T; Nakamura M; Motokawa S; Ishibashi H
    Arthritis Res Ther; 2011 May; 13(3):R72. PubMed ID: 21548952
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Influence of Janus kinase inhibition on interleukin 6-mediated induction of acute-phase serum amyloid A in rheumatoid synovium.
    Migita K; Koga T; Komori A; Torigoshi T; Maeda Y; Izumi Y; Sato J; Jiuchi Y; Miyashita T; Yamasaki S; Kawakami A; Nakamura M; Motokawa S; Ishibashi H
    J Rheumatol; 2011 Nov; 38(11):2309-17. PubMed ID: 21844139
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Inhibition of JAK-STAT Signaling Suppresses Pathogenic Immune Responses in Medium and Large Vessel Vasculitis.
    Zhang H; Watanabe R; Berry GJ; Tian L; Goronzy JJ; Weyand CM
    Circulation; 2018 May; 137(18):1934-1948. PubMed ID: 29254929
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Pharmacodynamic analysis of tofacitinib and basiliximab in kidney allograft recipients.
    Vafadari R; Quaedackers ME; Kho MM; Mol WM; Chan G; Weimar W; Baan CC
    Transplantation; 2012 Sep; 94(5):465-72. PubMed ID: 22960764
    [TBL] [Abstract][Full Text] [Related]  

  • 6. T cell signal transducer and activator of transcription (STAT) 4 and 6 are affected by adalimumab therapy in rheumatoid arthritis.
    Aerts NE; Ebo DG; Bridts CH; Stevens WJ; De Clerck LS
    Clin Exp Rheumatol; 2010; 28(2):208-14. PubMed ID: 20483042
    [TBL] [Abstract][Full Text] [Related]  

  • 7. JAK3/STAT6 Stimulates Bone Marrow-Derived Fibroblast Activation in Renal Fibrosis.
    Yan J; Zhang Z; Yang J; Mitch WE; Wang Y
    J Am Soc Nephrol; 2015 Dec; 26(12):3060-71. PubMed ID: 26032813
    [TBL] [Abstract][Full Text] [Related]  

  • 8. [Inhibitory effect and mechanism of tofacitinib on the secretion of cytokines by T cells in human peripheral blood].
    Wu K; Zhao J; Wu Q; Wu C
    Xi Bao Yu Fen Zi Mian Yi Xue Za Zhi; 2017 Nov; 33(11):1448-1455. PubMed ID: 29268845
    [TBL] [Abstract][Full Text] [Related]  

  • 9. The JAK inhibitor tofacitinib regulates synovitis through inhibition of interferon-γ and interleukin-17 production by human CD4+ T cells.
    Maeshima K; Yamaoka K; Kubo S; Nakano K; Iwata S; Saito K; Ohishi M; Miyahara H; Tanaka S; Ishii K; Yoshimatsu H; Tanaka Y
    Arthritis Rheum; 2012 Jun; 64(6):1790-8. PubMed ID: 22147632
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Interleukin-7 promotes the survival of human CD4+ effector/memory T cells by up-regulating Bcl-2 proteins and activating the JAK/STAT signalling pathway.
    Chetoui N; Boisvert M; Gendron S; Aoudjit F
    Immunology; 2010 Jul; 130(3):418-26. PubMed ID: 20465565
    [TBL] [Abstract][Full Text] [Related]  

  • 11. In vitro and in vivo analysis of a JAK inhibitor in rheumatoid arthritis.
    Tanaka Y; Maeshima K; Yamaoka K
    Ann Rheum Dis; 2012 Apr; 71 Suppl 2():i70-4. PubMed ID: 22460142
    [TBL] [Abstract][Full Text] [Related]  

  • 12. CP-690,550, a therapeutic agent, inhibits cytokine-mediated Jak3 activation and proliferation of T cells from patients with ATL and HAM/TSP.
    Ju W; Zhang M; Jiang JK; Thomas CJ; Oh U; Bryant BR; Chen J; Sato N; Tagaya Y; Morris JC; Janik JE; Jacobson S; Waldmann TA
    Blood; 2011 Feb; 117(6):1938-46. PubMed ID: 21106989
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Tofacitinib regulates synovial inflammation in psoriatic arthritis, inhibiting STAT activation and induction of negative feedback inhibitors.
    Gao W; McGarry T; Orr C; McCormick J; Veale DJ; Fearon U
    Ann Rheum Dis; 2016 Jan; 75(1):311-5. PubMed ID: 26353790
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Staphylococcal enterotoxins modulate interleukin 2 receptor expression and ligand-induced tyrosine phosphorylation of the Janus protein-tyrosine kinase 3 (Jak3) and signal transducers and activators of transcription (Stat proteins).
    Nielsen M; Svejgaard A; Röpke C; Nordahl M; Odum N
    Proc Natl Acad Sci U S A; 1995 Nov; 92(24):10995-9. PubMed ID: 7479924
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Anti-inflammatory potential of PI3Kδ and JAK inhibitors in asthma patients.
    Southworth T; Plumb J; Gupta V; Pearson J; Ramis I; Lehner MD; Miralpeix M; Singh D
    Respir Res; 2016 Oct; 17(1):124. PubMed ID: 27716212
    [TBL] [Abstract][Full Text] [Related]  

  • 16. The JAK inhibitor, tofacitinib, reduces the T cell stimulatory capacity of human monocyte-derived dendritic cells.
    Kubo S; Yamaoka K; Kondo M; Yamagata K; Zhao J; Iwata S; Tanaka Y
    Ann Rheum Dis; 2014 Dec; 73(12):2192-8. PubMed ID: 24013646
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Tofacitinib attenuates arthritis manifestations and reduces the pathogenic CD4 T cells in adjuvant arthritis rats.
    Gertel S; Mahagna H; Karmon G; Watad A; Amital H
    Clin Immunol; 2017 Nov; 184():77-81. PubMed ID: 28461107
    [TBL] [Abstract][Full Text] [Related]  

  • 18. CP-690550, a Janus kinase inhibitor, suppresses CD4+ T-cell-mediated acute graft-versus-host disease by inhibiting the interferon-γ pathway.
    Park HB; Oh K; Garmaa N; Seo MW; Byoun OJ; Lee HY; Lee DS
    Transplantation; 2010 Oct; 90(8):825-35. PubMed ID: 20697326
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Antibody-induced CD3-CD4 coligation inhibits TCR/CD3 activation in the absence of costimulatory signals in normal mouse CD4(+) T lymphocytes.
    Portolés P; de Ojeda G; Criado G; Fernández-Centeno E; Rojo JM
    Cell Immunol; 1999 Aug; 195(2):96-109. PubMed ID: 10448009
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Low dose CP-690,550 (tofacitinib), a pan-JAK inhibitor, accelerates the onset of experimental autoimmune encephalomyelitis by potentiating Th17 differentiation.
    Yoshida H; Kimura A; Fukaya T; Sekiya T; Morita R; Shichita T; Inoue H; Yoshimura A
    Biochem Biophys Res Commun; 2012 Feb; 418(2):234-40. PubMed ID: 22252297
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.